We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

User Satisfaction Using the ADI Insulin Pump

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00797771
First Posted: November 25, 2008
Last Update Posted: June 9, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
NiliMedix
  Purpose

Approximately 250,000 people worldwide are currently being treated with an insulin pump. This number is growing dramatically as these devices become smaller and more user-friendly. Insulin pumps allow for tight metabolic control and lifestyle flexibility while minimizing the number of hypoglycemic events.

The NiliMedix ADI Insulin Pump is an ambulatory, battery operated, rate programmable micro- infusion pump, designed for continuous delivery of insulin. A custom reservoir is driven by the pressure of insulin within it to deliver preset basal profiles and patient programmed bolus of insulin through custom infusion sets, into subcutaneous tissue.

This type of device requires extensive user interaction and education in order to ensure its safety. This study was designed to test the independent home-use of the NiliMedix ADI Insulin Pump, and to evaluate user's satisfaction.


Condition Intervention
Diabetes Device: "Adi" Insulin pump

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation of User Satisfaction Using the ADI Insulin Pump

Resource links provided by NLM:


Further study details as provided by NiliMedix:

Primary Outcome Measures:
  • User satisfaction regarding the "Adi" pump functioning will be evaluated by questionnaire. The questionnaire will be administrated during the last study visit [ Time Frame: End of study ]

Secondary Outcome Measures:
  • Number of severe hypoglycemic events [ Time Frame: during the study ]

Estimated Enrollment: 20
Study Start Date: December 2008
Study Completion Date: January 2010
Primary Completion Date: November 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A
"Adi" insulin pump users
Device: "Adi" Insulin pump
insulin delivery will be defined by the physician

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male/female age 18 years and up.
  • Subject is diagnosed as Type 1 Diabetes.
  • Pump Users for at least 6 months
  • HbA1c: less than 8.5%
  • Capable of reading pump screens in English.
  • Subject understands the study procedure.
  • Subject is willing to sign the informed consent form and comply with the study requirements.

Exclusion Criteria:

  • Major physical, motor, mental, behavioral, or psychiatric limitations.
  • Subject experienced a severe hypoglycemic episode that led to hospitalization during the last 6 months.
  • Subject experienced an episode of Ketoacidosis during the last 6 months, while using an insulin pump.
  • Concurrent additional major illness.
  • Subject objects to the study protocol.
  • Physician objection
  • Concurrent participation in other study.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00797771


Locations
Israel
Schnieder Children's Medical Center
Petach-Tikva, Israel, 49202
Sponsors and Collaborators
NiliMedix
Investigators
Principal Investigator: Shlomit Shalitin, MD Schnieder Children's Medical Center Israel
  More Information

Responsible Party: Dr. Hanna Levy, NiliMedix
ClinicalTrials.gov Identifier: NCT00797771     History of Changes
Other Study ID Numbers: NM-HU-01
First Submitted: November 23, 2008
First Posted: November 25, 2008
Last Update Posted: June 9, 2011
Last Verified: June 2009

Keywords provided by NiliMedix:
Insulin delivery

Additional relevant MeSH terms:
Insulin, Globin Zinc
Insulin
Hypoglycemic Agents
Physiological Effects of Drugs